Ross Merkin, MD
Clinical Fellow
Research & Publications
Biography
Research Summary
My research focuses on toxicities that occur as a result of immunotherapy. Immune checkpoint inhibitors leverage the immune system to kill cancer cells that have learned to evade the immune system, and have led to dramatic improvements in patient survival and quality of life in some cancers. Side effects from these medications range from mild to severe and may require treatment with immunosuppressive medications such as steroids. By gaining a better understanding of how these toxicities occur we can learn how to treat them better and allow for optimal cancer treatment with immune checkpoint inhibitors.
Research Interests
Immunoproteins; Skin Neoplasms; Thoracic Neoplasms; Biomarkers
Selected Publications
- Internal Medicine Resident Work Absence During the COVID-19 Pandemic at a Large Academic Medical Center in New York City.Merkin R, Kruger A, Bhardwaj G, Kajita GR, Shapiro L, Galen BT. Internal Medicine Resident Work Absence During the COVID-19 Pandemic at a Large Academic Medical Center in New York City. Journal Of Graduate Medical Education 2020, 12: 682-685. PMID: 33391591, PMCID: PMC7771614, DOI: 10.4300/JGME-D-20-00657.1.
- Keratin 17 is overexpressed and predicts poor survival in estrogen receptor–negative/human epidermal growth factor receptor-2–negative breast cancerMerkin RD, Vanner EA, Romeiser JL, Shroyer ALW, Escobar-Hoyos LF, Li J, Powers RS, Burke S, Shroyer KR. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor–negative/human epidermal growth factor receptor-2–negative breast cancer Human Pathology 2016, 62: 23-32. PMID: 27816721, DOI: 10.1016/j.humpath.2016.10.006.
- 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate CancerHillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer Journal Of Nuclear Medicine 2013, 54: 1369-1376. PMID: 23733925, DOI: 10.2967/jnumed.112.116624.